Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's parent firm. The company is the main supplier of fill-finish work – involving filling and packaging syringes and injection pens in sterile conditions – for Novo's popular weight-loss drug, Wegovy. Novo Holdings' takeover follows a strategic review undertaken as part of Catalent's settlement with activist investor Elliott Investment Management in August.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles